The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction.
Saved in:
| Title: | The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction. |
|---|---|
| Authors: | Metsemakers SJJPM; Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands. Electronic address: Sanne.Metsemakers@radboudumc.nl., Hermens RPMG; Department of IQ Health, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands., Ector GICG; Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands., Blijlevens NMA; Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands., Govers TM; Medip Analytics, Nijmegen, Gelderland, The Netherlands; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands. |
| Source: | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2025 Feb; Vol. 28 (2), pp. 224-232. Date of Electronic Publication: 2024 Dec 27. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
